Q32 Bio QTTB
Q32 Bio Q2 FY24: revenue $0; diluted EPS −$1.42
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-093305
- Document
- 10-Q
Key figures from this report
These are the numbers Q32 Bio reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$17.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$1.42No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$97.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$22.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Kiora Pharmaceuticals KPRX public float $10M, Jun 30, 2025
- Brainstorm Cell Therapeutics BCLI public float $10M, Jun 30, 2025
- Scienture Holdings SCNX public float $10M, Jun 30, 2025
- LeonaBio ATHA public float $10M, Jun 30, 2025
- Mannatech MTEX public float $10M, Jun 30, 2025
